Chief Scientific Officer · Neurogene Inc. (NGNE)

Stuart Cobb

A named executive officer of Neurogene in every fiscal year CompBrief holds from FY2022 to FY2023. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$784,324

Salary $362,258Stock awards $0Bonus $116,549

FY2022: $458,987

5th of 6 named executive officers at Neurogene by FY2023 total.

6 named officers on file for Neurogene, FY2023

Stuart Cobb’s pay file — $29

  • 2 fiscal years of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Neurogene’s whole pay program stands against its peers

  • Neurogene’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on NGNE→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 26, 2024 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Stuart Cobb’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Stuart Cobb compensation by year

Neurogene Summary Compensation Table · all 2 fiscal years held
In US dollars, as Neurogene reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2022FY2023
Salary$341,256$362,258
Bonus$117,731$116,549
Stock awards$0$0
Option awards$0$305,517
Non-equity incentive$0$0
Pension and deferred compensation$0$0
All other$0$0
Total$458,987$784,324

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Neurogene Inc. DEF 14A filed April 26, 2024, accession 0001404644-24-000043, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Neurogene Inc. filed document, accession 0001404644-24-000043. Every figure is read from that document and cited to the page and table it appears in. Filed April 26, 2024.

$459K
$784K
FY22
FY23
SalaryBonusOption awards

Equity holdings

unvested awards at FY2023 year-end
TypeUnvested unitsValue at year-endExercise price
Option6,717—$23.02
Option22,680—$18.39
Option4,725—$10.71

Per the Outstanding Equity Awards at Fiscal Year-End table in Neurogene Inc.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

7 Form 4 lines since the FY2023 proxy (filed April 26, 2024)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-03-13Sale10b5-13,991$20.4133,303
2026-03-13Sale10b5-12,658$21.3430,645
2026-03-13Sale10b5-1148$22.0830,497
2026-02-20Grant or award—16,500$0.0037,294
2025-05-14Sale10b5-16,797$15.1520,794
2025-03-26Grant or award—7,200$0.0027,591
2025-03-26Grant or award derivative—42,900$0.0042,900

The 7 most recent of 7 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

Neurogene’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
Donna CochenerFormer Interim Chief Executive Officer and General Counsel$1,827,432
Sean SmithFormer Interim Chief Financial Officer$1,809,783
Christine MikailPresident and Chief Financial Officer$1,132,484
Rachel McMinnFounder and Chief Executive Officer$1,080,629
Stuart Cobb · this pageChief Scientific Officer$784,324
Jonathan DrachmanFormer Chief Executive Officer and President$549,983

The full Neurogene compensation record

free company brief

This page is one person within Neurogene's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Neurogene's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Stuart Cobb's compensation dossier · One-time report. No refunds.